Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s Disease
| العنوان: | Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s Disease |
|---|---|
| المؤلفون: | Bengt Winblad, Christian A. Vedeler, Angel Cedazo-Minguez, Einar K. Kristoffersen, Lasse Melvaer Giil, Tove Ragna Reksten, Jan Erik Nordrehaug, Dag Aarsland, Anders Lund |
| المصدر: | Journal of Alzheimer's Disease. 47:523-529 |
| بيانات النشر: | IOS Press, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Enzyme-Linked Immunosorbent Assay, medicine.disease_cause, Receptor, Angiotensin, Type 2, Autoimmunity, Cerebrospinal fluid, Alzheimer Disease, Internal medicine, Diabetes mellitus, medicine, Humans, Dementia, Longitudinal Studies, Aged, Autoantibodies, Aged, 80 and over, Norway, business.industry, General Neuroscience, Autoantibody, General Medicine, Middle Aged, medicine.disease, Psychiatry and Mental health, Clinical Psychology, Endocrinology, Blood pressure, Biomarker (medicine), Female, Geriatrics and Gerontology, Alzheimer's disease, Mental Status Schedule, business, Biomarkers |
| الوصف: | Background: Autoantibodies with agonist function are described in cardiovascular disorders. Since vascular risk factors are associated with an increased risk for Alzheimer’s disease (AD), we investigated a potential association between antibodies to the angiotensin 2 type 1 receptor (anti-AT1R) and AD. Objective: The primary objective of this study was to investigate the association between anti-AT1R and AD. The secondary objective was to investigate the association between clinical or biomarker features of AD and anti-AT1R. Methods: Samples from patients with mild AD participating in a longitudinal study in Western Norway (n = 92, 65 [71%] females, mean age 74.8 [range 50–89]) and age- and gender-matched healthy controls (n = 102) were included. Cerebrospinal fluid (CSF) AD biomarkers were assessed in a subgroup of patients. Patients were examined annually, including Mini-Mental State Examination. ELISA was used to measure anti-AT1R in serum. Non-parametric tests were used for statistical calculations and a p < 0.05 was considered significant. Results: AD patients had significantly higher levels of anti-AT1R compared with healthy controls (10.2 U/mL versus 8.1 U/mL, p = 0.04). This difference was found only in patients without hypertension and diabetes. Anti-AT1R levels correlated with CSF total tau (p = 0.03) and phosphorylated tau (p = 0.03) levels, and inversely with blood pressure in AD (Spearman R −0.277, p = 0.008). Discussion: AD is associated with increased levels of anti-AT1R, and the antibodies correlated with CSF total, and phosphorylated tau levels. Further research is needed to understand the blood pressure response in AD without hypertension and a potential link between tau and anti-AT1R in AD. |
| تدمد: | 1875-8908 1387-2877 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31147bf9444eb5d418cd17f393df22acTest https://doi.org/10.3233/jad-150053Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....31147bf9444eb5d418cd17f393df22ac |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18758908 13872877 |
|---|